Log in

Devonian Health Group Stock Price, News & Analysis (CVE:GSD)

C$0.17
-0.05 (-22.73 %)
(As of 10/22/2019 01:40 AM ET)
Today's Range
C$0.17
Now: C$0.17
C$0.19
50-Day Range
C$0.16
MA: C$0.24
C$0.35
52-Week Range
C$0.12
Now: C$0.17
C$0.60
Volume19,500 shs
Average Volume14,647 shs
Market CapitalizationC$11.71 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Devonian Health Group Inc., a pharmaceutical company, engages in the development of botanical drugs. Its lead product candidate is Thykamine, which is in Phase II clinical trials for the treatment of ulcerative colitis and atopic dermatitis. It also develops value-added products for dermo-cosmetics. The company was incorporated in 2013 and is headquartered in Québec, Canada.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone450-937-6696

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$6.95 million
Cash FlowC$0.01 per share
Book ValueC$0.16 per share

Profitability

Miscellaneous

EmployeesN/A
Market CapC$11.71 million
Next Earnings DateN/A
OptionableNot Optionable

Receive GSD News and Ratings via Email

Sign-up to receive the latest news and ratings for GSD and its competitors with MarketBeat's FREE daily newsletter.


Devonian Health Group (CVE:GSD) Frequently Asked Questions

What is Devonian Health Group's stock symbol?

Devonian Health Group trades on the Canadian Venture Exchange (CVE) under the ticker symbol "GSD."

Has Devonian Health Group been receiving favorable news coverage?

News articles about GSD stock have trended somewhat positive recently, according to InfoTrie. The research group rates the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Devonian Health Group earned a coverage optimism score of 0.8 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Devonian Health Group.

Who are some of Devonian Health Group's key competitors?

Who are Devonian Health Group's key executives?

Devonian Health Group's management team includes the folowing people:
  • Dr. Andre P. Boulet, Chairman, Pres, CEO & Sec. (Age 60)
  • Ms. Colette Laurin, CFO & Corp. Controller
  • Mr. Tarique Sayed, Sec. & Director

How do I buy shares of Devonian Health Group?

Shares of GSD and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Devonian Health Group's stock price today?

One share of GSD stock can currently be purchased for approximately C$0.17.

How big of a company is Devonian Health Group?

Devonian Health Group has a market capitalization of C$11.71 million and generates C$6.95 million in revenue each year. View Additional Information About Devonian Health Group.

What is Devonian Health Group's official website?

The official website for Devonian Health Group is http://www.groupedevonian.com/.

How can I contact Devonian Health Group?

The company can be reached via phone at 450-937-6696.


MarketBeat Community Rating for Devonian Health Group (CVE GSD)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  21 (Vote Outperform)
Underperform Votes:  24 (Vote Underperform)
Total Votes:  45
MarketBeat's community ratings are surveys of what our community members think about Devonian Health Group and other stocks. Vote "Outperform" if you believe GSD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GSD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/22/2019 by MarketBeat.com Staff

Featured Article: What is Compound Interest?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel